close

Non-Invasive Prenatal Screening Plus, NIPS+


NIPS+ detect common chromosomal aneuploidy, selected microdeletions syndromes and selected skeletal dysplasia genetic mutations

Read More

Introduction


■ INTERNATIONAL COOPERATION


Cooperate with illumina® and introduce the patented technique, SAFeR™, with its clinical database, which was and report will be given in only 8 working days and applied in many medical centers.



■ SCREENING UPGRADE


With the global database of 1,000,000 clinical cases, we upgrade the screening and guarantee by choosing and analyzing the 20 chromosomal micro deletions.



■ 8 WORKING DAYS


It is assured by SNQ (Symbol of National Quality) that the whole process will all be accomplished in Taiwan with high quality and standard, and the screening result can be received in 8 working days only.



■ NON-INVASIVE


It is recommended by society of OB/GYN and has become a trend in the world. The non-invasive procedure won’t lead to miscarriage and infection, which is safe without risk.



■ 10 WEEKS SCREENING


The earlier you detect, the more relieved you will be. NIPS+ can be applied for pregnant women at 10 weeks of gestation. The detection rate is up to 99.5%*.


*The detection rate of aneuploidy diseases, such as Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), are 99.5%. While the detection rate of 20 chromosomal micro deletions are 99%. .



■ CLINICAL SUPPORT


With the complete and detailed reports, physicians examine thoroughly and provide the service of heredity consultation.



According to the rules of Ministry of Health and Welfare, this screening can’t expose genders of fetus.

Indication


American Congress of Obstetricians and Gynecologists (ACOG) proved the effectiveness of non-invasive prenatal screening in December, 2012. After SOFIVA Genomics and illumina® co-construct a complete database, we even add the analysis of chromosomal microdeletions which provides pregnant women guarantee.



◆ Women who are ≧ 34-year-old


◆ Women who worry about the risk of invasive test


◆ Women who find abnormal ultrasound screening


◆ Women who have doubt of chromosomal aneuploidies


◆ Women who have doubt of chromosomal aneuploidies



* Ref:Obstet Gynecol. 2012;120(6)



Note:


• Pregnant women with multiple gestation are not suggested with NIPS+


• Pregnant women themselves with chromosomal aneuploidy or micro deletions diagnostic results are not suggested with NIPS+


• According to the rules of Ministry of Health and Welfare, this screening can’t expose genders of fetus.。


• NIPS+ mainly focuses on screening the Trisomy 13, Trisomy 18 and Trisomy 21 chromosome and the selected 20 chromosomal micro deletions, while not every chromosomal abnormality can be detected. Therefore, chromosomal abnormalities, such as other micro deletions, duplications, copy number variations, balanced or unbalanced translocations, inversions, uniparental disomy, mosaicism, etc., are not included in the scope of detection.

Description


THE ONLY AUTHORIZED COMPANY OF illumina® IN TAIWAN



The outstanding genetic screening technique and strength of SOFIVA Genomics win the favor of illumina®, the leading company of gene sequencing in the world, and the cooperation has started since 2015 to provide pregnant women with excellent international screening services.



SOFIVA Genomics collaborates with illumina®, introduces the patented technique, SAFeR™, which is win the favor of illumina®, the leading company of gene sequencing in the world, and the cooperation have started since 2015 to provide pregnant women with excellent international screening services. In Taiwan, NIPS+ is awarded National Biotechnology & Medical Care Quality Award and Symbol of National Quality (SNQ). By combining the conscientious clinical data and the innovative thinking, we build a precise and comprehensive prenatal chromosomal screening with high accuracy.

Patient Story


How It Works


1. Ask your physician about SOFIVA NIPS+ prenatal test, sign a consent form and get your blood drawn


2. Blood sample transports to our clinical lab. We obtain cell-free fetal DNA by plasma separation and DNA extract


3. Perform high throughput sequencing by NGS for screening cell-free fetal DNA


4. Complete bioinformatics analysis (chromosomal aneuploidies and selected 20 common microdeletions)


5. Providing results in 8 working days with professional medical genetic physicians' confirmation

Others


FACTORS of NIPS+



Explicit and detailed results, detect 23 pairs of chromosomes & microdeletion syndromes


The redraw rate and failure rate are less than 0.1%, which decreases burdens of pregnant women


Won’t be influenced by physiological conditions of pregnant women, which could exclude external factors leading to errors; moreover, we don't need father's specimen


Provide the most appropriate and accurate screening results under any different condition, such as ages, and types of fertilization (donated-egg fertilization or in vitro fertilization)